Hereditary Angioedema Market to wintness growth by 2032, Estimates DelveInsight | BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, Shire, Pharming Group, Takeda

Hereditary Angioedema Market to wintness growth by 2032, Estimates DelveInsight | BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, Shire, Pharming Group, Takeda
Hereditary Angioedema Market

DelveInsight’s “Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hereditary Angioedema market report also covers emerging drugs, current treatment practices, Hereditary Angioedema market share of the individual therapies, current and forecasted Hereditary Angioedema Market Size from 2019 to 2032 segmented by seven major markets.

 

To know more about the Hereditary Angioedema report offerings, click here: Hereditary Angioedema Market Forecast

 

Some facts of Hereditary Angioedema Market Report

  • According to DelveInsight, Hereditary Angioedema market size is expected to reach USD XX Million by 2032.
  • In 7MM, Hereditary Angioedema market size was USD 2,300 million in 2022.
  • Among all the 7MM, the US consistently captured the highest Hereditary Angioedema market with nearly USD 1,900 million estimated in 2022, which is expected to grow during the forecasted period (2023-2032).
  • Key Hereditary Angioedema Companies: BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, Shire, Pharming Group, Takeda Pharmaceuticals, BIOCRYST PHARMACEUTICALS, INC., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., CENTOGENE N.V., and Sanofi, and many others.
  • Key Hereditary Angioedema Therapies: Sebetralstat/KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorsen, STAR-0215, PHA121 (PHA-022121), and others.
  • The diagnosed prevalent cases of HAE in the 7MM varied according to gender, with prevalent cases higher in females than males. Assessments, as per DelveInsight’s analysts, show that the overall diagnosed prevalent cases of HAE in females was 8,500, while it was 5,400 in males in 2022, these cases are subject to rise in the coming years.
  • The Hereditary Angioedema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics

 

Hereditary Angioedema Overview

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon. The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum.

 

Request for free sample pages @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market

 

Key Benefits of Hereditary Angioedema Market Report

  • Hereditary Angioedema market report provides an in-depth analysis of Hereditary Angioedema Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
  • The Hereditary Angioedema market report will help in developing business strategies by understanding the Hereditary Angioedema Market trends & developments, key players and future market competition that will shape and drive the Hereditary Angioedema market in the upcoming years.
  • The Hereditary Angioedema market report covers Hereditary Angioedema current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Hereditary Angioedema market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

 

Hereditary Angioedema Market

The landscape of therapeutic options for patients with HAE has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration. Owing to the launch of upcoming therapies, market size shall increase during forecast period (2019-2032).

The Hereditary Angioedema market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Angioedema market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Hereditary Angioedema market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.

 

Request for free sample pages @ Hereditary Angioedema Market Forecast

 

Hereditary Angioedema Epidemiology

The Hereditary Angioedema epidemiology section covers insights about historical and current Hereditary Angioedema patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Hereditary Angioedema Drugs Uptake and Key Market Players

The Hereditary Angioedema Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched in the market during the study period. The analysis covers Hereditary Angioedema market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow HAE patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies.

 

Request for free sample pages @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market

 

Hereditary Angioedema Companies:

Some of the Hereditary Angioedema companies working in the Hereditary Angioedema Market are BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, CSL Behring, Shire, Pharming Group, Takeda Pharmaceuticals, BIOCRYST PHARMACEUTICALS, INC., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., CENTOGENE N.V., and Sanofi, and many others.

 

Hereditary Angioedema Therapies:

Hereditary Angioedema Drugs Covered are BCX7353, IONIS-PKK-LRx, KVD900, CSL312, and many others.

 

Emerging Hereditary Angioedema drugs Uptake:

  • TAKHZYRO (lanadelumab, Takeda) is a newly-developed monoclonal antibody approved for long-term prophylaxis in HAE patients aged 12 and older. It inhibits plasma kallikrein, preventing the formation of BK and, therefore, decreasing the risk of developing angioedema. Recently, in Feb 2023, the US FDA also approved Takeda’s Takhzyro (lanadelumab-flyo) to prevent HAE attacks in children 2 years of age and older.
  • CINRYZE (Takeda) is an IV human plasma-derived C1-INH approved for patients aged 6 and older. CINRYZE requires IV administration every 3–4 days, and some patients may need higher than typical doses to achieve a reduction in attacks.
  • HAEGARDA (CSL Behring) was approved for long-term prophylaxis for adults and adolescents to fulfill this unmet need. It is a human plasma-derived C1-INH, taken twice weekly as an SC injection. HAEGARDA as a prophylaxis treatment is more effective than CINRYZE and attracted a greater number of patients due to the ease of administration.
  • Potential drug targets include inhibiting factor XII (e.g., with a blocking antibody), plasma kallikrein inhibitor, inhibiting the cleavage of prekallikrein, and blocking the bradykinin-B2-receptor. Along with this, few gene therapies are developing for treating HAE; this will help treat the newly identified mutations such as FXII and PLG HAE.

 

Request for free sample pages @ https://www.delveinsight.com/sample-request/hereditary-angioedema-market

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Hereditary Angioedema Competitive Intelligence Analysis

4. Hereditary Angioedema Market Overview at a Glance

5. Hereditary Angioedema Disease Background and Overview

6. Hereditary Angioedema Patient Journey

7. Hereditary Angioedema Epidemiology and Patient Population

8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Angioedema Unmet Needs

10. Key Endpoints of Hereditary Angioedema Treatment

11. Hereditary Angioedema Marketed Products

12. Hereditary Angioedema Emerging Therapies

13. Hereditary Angioedema Seven Major Market Analysis

14. Attribute Analysis

15. Hereditary Angioedema Market Outlook (7 major markets)

16. Hereditary Angioedema Access and Reimbursement Overview

17. KOL Views on the Hereditary Angioedema Market.

18. Hereditary Angioedema Market Drivers

19. Hereditary Angioedema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services


Posted

in

by

Tags: